Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis The enzyme Apel/Ref-1, via its redox function, enharces the DNA binding activity of transcription factors that are asscciated with the progression of carner The present invention describes the use of agents to selectively inhibit the redox function of Apel/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis In addition, Apel/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity Further, Apel/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component
